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Background. There are few reports of HIV viral load (VL) testing among patients on ART in Vietnam. Methods. From a public
clinic in Ho Chi Minh City (HCMC), we reviewed cases of VL measurements from adults on ART. Results. We identiﬁed 228 cases.
Median age was 30 years (27–34), 85% were male, and 77% had a history of IDU. The mean ART duration was 26 months (95% CI
25–27); d4T/3TC/NVP was the most common regimen. Viral suppression was seen in 160/228 (70%). Viremia (>1000copies/mL)
was associated with prior ART exposure (OR 5.68, P<. 0001) and immunologic failure (OR 4.69, P = .0001). Targeted testing
accounted for 13% of cases, only half of which yielded viremia. Conclusion. We demonstrate a high HIV suppression rate among
patients on ART in HCMC, Vietnam. In this setting, routine testing detects viremia missed by targeted testing.
1.Introduction
Vietnam is a country with one of the highest prevalences
of HIV in Southeast Asia. With an estimated prevalence of
293000 people in 2007 (approximately 0.5% of the general
population), the HIV epidemic is primarily concentrated in
urban areas among key high-risk populations, the majority
of which are injection drug users (IDU), and to a lesser
extent, female sex workers (FSWs) and men who have
sex with men (MSM) [1, 2]. Eﬀorts to confront the HIV
epidemic in Vietnam face a high burden of patients with
comorbid substance abuse and limited resources.
International eﬀorts to scale up antiretroviral therapy
(ART) have greatly improved funding for treatment in
Vietnam,allowingforapproximately14969peopletoreceive
ART as of 2007 [3]. The success of ART programs has been
documented in resource-limited settings throughout the
world [4]. However, cohorts examining the eﬀectiveness of
ART programs in low-income countries traditionally consist
of countries with a low prevalence of IDU, the majority of
which are in Africa [5, 6]. Thus, there is less information
regarding ART scale-up eﬀorts in resource-limited settings
withahighburdenofcomorbidIDU.Onlysince2009hasthe
ﬁrstreportofARTamongIDUinVietnambeendocumented
[7].
Virologic suppression is the measure of successful
antiretroviral therapy. The cost of viral load monitoring,
however, has been prohibitive in resource-limited settings..
The World Health Organization (WHO) has recommended
an algorithm using clinical and immunologic criteria to
assess treatment failure in the absence of viral load testing
which has become standard of care in many resource-
limited settings[8].Theconcernhasbeenraisedthatdelayed
recognition of treatment failure may lead to prolonged use
of failing regimens and ampliﬁcation of drug resistance [9].
This concern may be most important in populations at
highest risk for failure including those with active substance
abuse.2 AIDS Research and Treatment
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HIV clinic located in District 6 (D.6) of Ho Chi Minh
City (HCMC), Vietnam, viral load (VL) testing has been
available in a limited capacity since 2005. Virologic testing
has been used principally as a conﬁrmatory test targeted
at patients suspected of failing based on WHO criteria of
clinical or immunologic failure. In December 2007, as part
of a quality improvement process, a program of routine viral
load surveillance was implemented at the An Hoa OPC.
The goals of this study were to document ART eﬀorts in
a resource-limited setting with high prevalence of IDUs,
to identify high-risk groups for failure who may beneﬁt
from more frequent monitoring or other interventions and
to assess the potential for delayed diagnosis of treatment
failure when using targeted testing based on clinical and
immunologic criteria.
2. Methods
2.1. Site and Population. Located in District 6 (D.6), An
Hoa Outpatient Center (OPC) is funded by USAID and the
US President’s Emergency Plan for AIDS Relief (PEPFAR)
and has been operated by the French nongovernmental
organization M´ edicins du Monde (MdM) since 2003. An
Hoa Outpatient OPC is one of 75 PEPFAR clinical sites, with
additional oversight by the Vietnamese Ministry of Health
(MOH), that provides ART- and HIV-related services to one
of the HCMC’s 18 inner city districts.
Available ﬁrst-line three-drug ART regimens are con-
sistent with WHO standards which include two nucleoside
reverse transcriptase inhibitors (either stavudine (d4T) +
lamivudine (3TC) or zidovudine (AZT) + lamivudine
(3TC)) with one non-nucleoside reverse transcriptase
inhibitor (either nevirapine (NVP) or efavirenz (EFV))
[8]. All patients preparing to initiate ART through the An
Hoa OPC must undergo pretherapy adherence counseling
sessions. Once initiated, patients are scheduled to undergo
clinical assessments with a physician and nursing at weeks 2,
4, 8, 12, 16, 24, 32, 40, and 48. Routine visits are scheduled
every 2 to 6 months afterwards. Per MOH guidelines, once
stable on ART, patients must come to the OPC monthly to
receive their ART supply. Additionally, patients are seen by
an adherence counselor at weeks 2, 4, 8, 24, and 48. CD4
counts are routinely obtained 12, 24, and 48 weeks and every
6 months afterwards.
Treatment failure is suspected if after one year of therapy,
patients exhibit immunologic failure (fall to baseline level
CD4 count, 50% fall in CD4 count from posttreatment peak,
orCD4countspersistently<100/mm3)and/orclinicalfailure
(new or recurrent WHO stage IV condition) according
to WHO criteria [10]. Switching to second-line regimen
involves a thorough committee review by specialists at the
Hospital for Tropical Disease in Ho Chi Minh City.
Viral load (VL) testing is available at the An Hoa OPC
in a limited capacity. During the dates from 12/1/2007
to 2/28/2009 VL testing was performed according to two
distinct approaches the following.
(1) Targeted testing to conﬁrm virologic failure among
those suspected of treatment failure and who were
in consideration for 2nd-line therapy. This approach
was done with funding from the US CDC based on
the Vietnamese Ministry of Health and is available to
all PEPFAR sites in HCMC.
(2) Routine testing to screen for subclinical virologic
failure for those on ART for greater than one year.
This approach was internally funded through MdM
and has been in practice since 12/1/07. Under this
approach, patients established on ART for greater
than one year received one-time VL testing as part of
a routine visit (as stated above).
All VL samples were sent to an oﬀsite facility at the Pasteur
Institute of HCMC, where they were assessed based on real-
time reverse transcriptase PCR assay (Generic HIV viral
load assay, Biocentric, Bandol, France) with a threshold for
detection of VL of 250copies/mL.
2.2. Data Collection. We reviewed cases of VL testing per-
formed at the An Hoa OPC between the dates of 12/1/07 and
2/28/09. Included for review were adult patients (>18 years)
on ART for greater than one year while actively registered
at the An Hoa OPC. We excluded patients younger than 18
years of age, and those who had been on ART for less than
one year in duration from date of registration to An Hoa
OPC.
An onsite database managed by trained nursing staﬀ
was used to identify cases for review. In situations where
multipleVLmeasurementsweresequentiallyperformedona
single patient, the initial date of VL testing was used for case
identiﬁcation.
Medical records were reviewed and abstracted for demo-
graphic data (e.g., age and sex), self-reported history of
IDU, date of registration to the AnHoa OPC, date of ART
initiation, 1st-line ART regimen, duration of ART at time
of VL testing, baseline CD4, CD4 at time of VL testing,
prior ART exposure, adherence, history of immunologic and
clinical failure, switch to 2nd-line regimen, and approach
used to perform VL testing, that is, targeted or routine
(nontargeted). Current and prior history of IDU was not
distinguished.
SigniﬁcantviremiawasdesignatedasaVLofgreaterthan
1000 copies per milliliter. Virologic failure, as deﬁned by the
WHO, was designated as VL greater than 10000copies/mL.
Prior ART exposure was deﬁned as prior ART usage
not under the supervision of any MOH monitored site.
Immunologic failure was determined according to WHO
standards, that is, fall to baseline level CD4, 50% fall
posttreatment peak, or levels persistently <100/mm3 after
one year of ART. Clinical failure was determined by new
or recurrent WHO stage IV condition. Adherence was
designated as “Good” if patient had >95% self-reported
adherence rate in the preceding month, and “Poor” if the
patient had <95%.
Descriptive statistics were generated for demographic
and clinical parameters. Univariate associations between
demographic and clinical factors and the presence of signif-
icant viremia were tested by means of chi-square statistics.AIDS Research and Treatment 3
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Figure 1: Flow chart of adult patients on ART >1yrwhoreceived
VL testing and enrolled for review.
Multivariate logistic regression was used to control for
potential confounding factors.
This paper was approved by the Provincial AIDS Com-
mittee (PAC), Ministry of Health (MOH) of Ho Chi Minh
City, Vietnam.
3. Results
As of the end of February 2009, a total of 1028 patients were
registered as active at the An Hoa OPC. Seven hundred and
ﬁfty-eight patients were receiving ART, and 467 of whom
had been on ART for greater than one year’s duration. We
identiﬁed 235 unique cases of viral load measurements for
review. Seven were excluded because of age less than 18 years
yielding a total of 228 for our study (Figure 1).
Composite baseline characteristics are outlined in
Table 1. The majority of patients were male (85%) and had
a history of IDU (77%). The median age was 30 years
(interquartile range 27–34). The regimen of d4T/3TC/NVP
was the most common 1st-line regimen utilized (65%),
and 74% had documented Good adherence. Thirty percent
had prior ART exposure not under the supervision of a
MOH monitored site. The median CD4 count at time of
registration to the An Hoa OPC and time of VL testing was
57cell/μL and 239 cells/μL, respectively. The mean duration
of ART prior to VL testing was 26 months (95% CI 25–
27), and undetectable virus was exhibited in 160 of 228
cases (70%). Measurements below our designated threshold
of signiﬁcant viremia (1000copies/mL) were seen in 175 of
228 cases (77%).
In univariate analysis the odds of signiﬁcant viremia
were higher for those with prior ART exposure (P<. 0001),
Table 1: Baseline characteristics of patients on ART >1yr who
received VL testing, N = 228.
Characteristic
Male (%) 193 (85)
Female (%) 35 (15)
Age at study, median (interquartile range), years 30 (27–34)
Age at ART initiation, median (interquartile
range) years 27 (24–31)
IDU (%) 175 (77)
Prior ART exposure (%) 30 (13)
Duration of ARV at time of viral load testing,
mean (95% CI), months 26 (25–27)
Adherence: “Good” (%) 169 (74)
Adherence: “Poor” (%) 59 (26)
First-line regimen
AZT/3TC/EFV 4 (2)
AZT/3TC/NVP 14 (6)
D4T/3TC/EFV 61 (27)
D4T/3TC/NVP 149 (65)
CD4 cell count, median (interquartile range)
cells/μL
at registration to An Hoa OPC 57
(18–146)
at viral load testing 240
(144–366)
Documented immunologic failure (%) 39 (17)
Documented clinical failure (%) 14 (6)
Switch to 2nd line∗ (%) 13 (6)
VL testing
according to targeted approach (%) 29 (13)
according to routine approach (%) 199 (87)
IDU: injection drug use, VL: viral load.
ART: antiretroviral therapy.
AZT: zidovudine, D4T: stavudine, EFV: efavirenz.
NVP: nevirapine, 3TC: lamivudine.
∗Second-lineregimen:tenofovir(TDF)/lamivudine(3TC)/lopinavir(LPV).
preceding immunological failure (P<. 0001), clinical failure
(P = .024), and female sex (P = .0428) (Table 2). In
multivariate analysis, two factors remained strongly asso-
ciated with signiﬁcant viremia: prior ART exposure (OR
5.69, P<. 001) and history of immunologic failure (OR
4.69, P = .0001). There was an observed trend towards
increased viremia among women, but not enough women
were enrolled to ﬁnd a signiﬁcant diﬀerence (P = .066).
A comparison of targeted and routine testing is seen
in Table 3. Of all cases yielded for review, 13% (29)
came as a result of targeted testing. Only half (48%)
of cases targeted for testing yielded signiﬁcant viremia
(>1000copies/mL), and all but one of which had viro-
logic failure (>10,000copies/mL). The sensitivity of targeted
testing in detecting signiﬁcant viremia was 26% with a
positive predictive value of 50%. Approximately 80% of
those targeted had immunologic failure, 72% had prior ART4 AIDS Research and Treatment
Table 2: Characteristics of patients on ART >1 year according to result of VL testing, threshold VL 1000copies/mL.
Characteristics
VL < 1000
(N = 175)
VL > 1000
(N = 53) OR (95% CI)
P value
Univariate Multivariate
Gender: male (%) 153 (87) 40 (75) 0.44 (0.2–0.95) — —
Gender: female (%) 22 (13) 13 (25) 2.26 (1.05–4.88) .043 .066
IDU (%) 133 (175) 42 (79) 1.2 (0.57–2.55) .34 —
Prior ART exposure (%) 12 (7) 18 (34) 6.99 (3.09–15.8) <.0001 <.0001
Adherence: “Good” (%) 132 (75) 37 (70) 0.75 (0.38–1.49) .419 —
Adherence: “Poor” (%) 43 (25) 16 (30) 1.33 (0.67–2.62) — —
CD4 cell count, median (interquartile range) cells/uL
at time of registration to An Hoa OPC 59 (20–143) 50 (12–149) —— —
at time of viral load testing 267 (171–374) 167 (78–260) —— —
Documented immunologic failure (%) 19 (11) 18 (34) 4.2 (2.0–8.9) <.0001 .0001
Documented clinical failure (%) 7 (4) 7 (13) 3.6 (1.2–10.9) .024 —
IDU: injection drug use, ART: antiretroviral therapy.
OPC: outpatient center, VL: VIRAL load.
Table 3: Characteristics of patients on ART >1yr—targeted testing and routine testing.
Characteristic Targeted testing (N = 29) Routine testing (N = 199)
CD4 cell count, median (interquartile range) cells/μL
at time of registration to An Hoa OPC 45 (14–107) 59 (18–149)
at time of VL testing 78 (53–93) 267 (179–400)
Documented immunologic failure (%) 24 (83) 14 (7)
Documented clinical failure (%) 6 (21) 8 (4)
Switch to 2nd line (%) 9 (31) 3 (2)
Undetectable or VL < 1000copies/mL (%) 15 (52) 160 (80)
Signiﬁcant viremia (copies/mL)
High viremia: VL > 10000 (%) 13 (45) 14 (7)
Moderate viremia: 10000 > VL > 1000 (%) 1 (3) 25 (13)
ART: antiretroviral therapy.
OPC: outpatient center, VL: viral load.
exposure, and 21% had clinical failure, compared to 7%,
11%, and 4% of those who had routine testing, respectively.
4. Discussion
In our study, viral load testing was performed on 49.7% of
adult patients on ART for greater than one year attending
the An Hoa OPC, and 77% of whom had a history of IDU.
The mean duration of ART was 26 months, and the rate of
undetectable virus and viremia below 1000copies/mL was
70% and 77%, respectively.
The detectable threshold of our assay, 250copies/mL, is
one that is not commonly used in studies evaluating ART
eﬃcacy. A detectable threshold of 400copies/mL is what has
been traditionally used in assays from studies conducted in
resource-limited settings. In studies from Africa, the viral
load suppression rate has ranged between 66% and 82%
for patients on ART for duration of 26–48 weeks [11–13].
Our study found a comparable suppression rate at a longer
mean ART duration, 26 months, despite using a lower level
of detection (i.e., more sensitive assay), in a predominantly
IDU population. Since our study excluded patients on ART
for less than one year, there may have been a selection bias
towards patients more tolerant of and more compliant with
ART which could partially explain the relatively high viral
suppression rate observed.
Injection drug users have often been associated with
lower rates of virologic suppression [14, 15]. This is
traditionally attributed to incomplete adherence, and the
psychosocial instability that comes with drug-seeking behav-
ior [16, 17]. International treatment cohorts which have
documented the eﬀorts of ART programs in low income
countries(ART-LINC)haveexcludedresource-limitedcoun-
tries with higher rates of IDU [5, 6]. Amongst developingAIDS Research and Treatment 5
nations, China and Russia have been estimated to have the
highest rates of IDU [18]. Recently, the ﬁrst study examining
viral load suppression rates among 8 ART programs in
China revealed a VL suppression rate of 67% for patients
on 24 months of ART [19]. However, IDUs may have
been underrepresented in this study, as IDU associated
transmission was reported in only 8% of patients. Studies
documenting the VL response of ART programs in Russia
and Eastern Europe remain to be seen.
TheprogramattheAnHoaOPCdemonstratesasuccess-
ful campaign of viral suppression among an HIV population
with a high prevalence of IDU. The viral suppression rate
in the current study is similar to that seen in a cohort of
HIV positive drug users on ART in Hanoi, Vietnam [7].
It is notable however that IDU history was not statistically
associated with viremia in our study. This observation
perhaps is due to the lack of distinction between current
and former IDU activity in our patients. Former IDUs have
beenshowntohavesimilarVLsuppressionratestonon-IDU
patients on ART [14].
The observed trend towards increased viremia among
women is somewhat surprising in our study. It has been
noted that the HIV epidemic among women in Vietnam has
been greatly under-reported and under-recognized. Institu-
tional eﬀorts focus primarily on young male injection drug
users, leaving women not only less likely to get tested, but
also less likely to receive optimal care [20]. A combination
of several cultural factors, including stigma directed against
HIV-infected patients, poor education, and reluctance to
seek medical care, subordinate gender roles, may also work
to create a signiﬁcant barrier to the optimization of medical
care for HIV-infected women in Vietnam [21–23]. However,
given the relatively low number of women in our cohort,
our ﬁndings need to be interpreted with caution. Further
studies are needed to adequately address variables such as
gender diﬀerences in patterns of clinical utilization that may
be contributing to failure among HIV-infected Vietnamese
women on ART.
Prior unmonitored ART exposure was shown to be a sig-
niﬁcant risk factorfortreatment failure in our study. Patients
in developing countries with a history of unmonitored ART
usage are at risk of improper administration of medications
as well as exposure to substandard or counterfeit drugs.
Thesepatients areatrisknot onlyforharmfulsideeﬀectsbut
also for the development of HIV drug resistance. Our data
adds to the previous studies which suggest that patients with
priorARTshouldbemorecloselytargetedforsuspectedART
failure [24].
The signiﬁcant association of immunologic failure and
viremia in our study is not surprising. The history of HIV
showsthatimmunologic failurenaturallyfollowsprogressive
sustained viremia. Virologic failure predates immunologic
failure, which is followed by clinical failure. Thus, strictly
using immunologic and clinical monitoring, that is, the
WHO algorithm, as a method to identify ART failure will
invariably miss early virologic failure thus allowing for
extended viral replication under drug pressure and promote
drug resistance.
Multiple studies have shown that the application of the
WHO algorithm is a poor substitute for viral load testing,
lackingsensitivityandspeciﬁcityfordetectingtreatmentfail-
ure in resource-limited settings [12, 24–29]. Furthermore, in
settings with no capacity for viral load testing, strictly using
the WHO algorithm also leads to potential misclassiﬁcation
of treatment failure and premature switch to second-line
regimens [26, 30]. A recent study evaluating immunologic
monitoring in a resource-limited setting, found that only
42% of patients qualifying for immunologic failure had
detectable virus [26]. Our study also found a potential
for misclassiﬁcation as only 48% of those targeted had
signiﬁcant viremia.
T h eg o a lo ft a r g e t e dV Lt e s t i n g ,a sa d o p t e db yt h e
Vietnamese MOH in HCMC, is to reduce the likelihood
of premature switch to valuable second-line regimens.
However, as our study shows, given the insensitivity of the
criteria used for targeted testing, treatment failure may be
under-diagnosed and opportunities to intervene early will be
lost.
Our review suggests that routine testing has the potential
to identify patients with signiﬁcant viremia not identiﬁed by
targeted testing programs and thus prevent delayed recog-
nition of treatment failure. Implementing routine testing,
however,posesanumberoflogisticalbarriers[31].Decisions
regarding the use of virologic monitoring need to consider
the cost, frequency, and availability of follow-up testing
along with the risk of reducing access to treatment or other
necessary health services. Other factors that need to be
considered are the threshold for change in regimen and the
role of adherence interventions.
A major limitation in our study was the usage of single
viral load measurements. Low level viremia in our review is
diﬃcult to distinguish from “blips” clinically insigniﬁcant
episodes of nonsustained, transient low level viremia [32].
We designated a level of 1000copies/mL to represent
signiﬁcant viremia, as levels above this threshold have been
shown to be frequently associated with resistance, often
leading to therapy changes [31, 33]. However, using this
threshold, we potentially excluded those who may have
been experiencing persistently low viremia, thus possibly
under-diagnosing treatment failure.
Additionally, single viral load measurements are chal-
lenging to interpret without the appropriate infrastructure
for followup, that is, subsequent testing, resistance analysis,
and resources to target adherence. Our study was not
designed to assess followup, but data from our review
may be used in designing a protocol for follow-up testing
and targeted interventions. Targetedadherence interventions
have been shown to be successful in reducing viral load
breakthrough to undetectable levels in a resource-limited
setting [34].
5. Conclusions
In summary, we demonstrate a successful campaign of HIV
viral load suppression in HCMC, Vietnam, a resource-
limited area with a high prevalence of IDUs. We found that
An Hoa OPC patients well established on ART experienced6 AIDS Research and Treatment
a high viral load suppression rate comparable to that seen
in other studies. Signiﬁcant viremia was strongly associated
with immunologic failure and prior ART exposure. A trend
towards increased viremia was observed among women on
ART that warrants further investigation. Targeted testing,
based on the WHO algorithm, was a poor predictor of
virologic failure. Routine screening is better able to identify
patients on ART who experience signiﬁcant viremia. This
approach however requires a comprehensive structure for
followup and intervention; the costs of which need to be
considered on a site by site basis in resource-limited areas.
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